Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Klebsiella pneumoniae Resistant to All Beta-Lactame/Beta-Lactamase Inhibitor Combinations
Retrospective study compares clinical outcomes of ceftazidime−avibactam plus aztreonam in bloodstream infections, suggesting comparable effects to double carbapenem therapy.
Key Points
Ceftazidime−avibactam plus aztreonam was evaluated in 23 patients with bloodstream infections caused by K. pneumoniae.
The SOFA score on day 4 was statistically lower in the control group compared to treatment groups, indicating varied outcomes.
Patients with septic shock had a significantly higher prevalence among non-survivors, highlighting the severity of their condition.
Independent factors influencing mortality included PaO2/FiO2 ratio and lactate levels, emphasizing the importance of these metrics.